Clinical trial · Observational
Prognostic and Predictive Factors for Small Breast Tumors
Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (14)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Age at diagnosis | Other | — | UNRESOLVED |
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Endocrine therapy | Drug | Hormone Therapy | ALIAS |
| Estrogen receptor (ER) status | Other | — | UNRESOLVED |
| HER2-status | Other | — | UNRESOLVED |
| Herceptin | Drug | Trastuzumab | ALIAS |
| Intrinsic subgroups of breast cancer | Other | — | UNRESOLVED |
| Menopausal status at diagnosis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Women with T1ab breast cancer.
- interventionNames
- Drug: Endocrine therapy
- Radiation: Radiotherapy
- Drug: Herceptin
- Drug: Chemotherapy
- Procedure: Type of breast cancer surgery
- Other: Age at diagnosis
- Other: Screen detected tumor
- Other: Menopausal status at diagnosis
- Other: Tumor size
- Other: Estrogen receptor (ER) status
- Other: Tumor grade
- Other: HER2-status
- Other: Intrinsic subgroups of breast cancer
- Other: Nodal status
Primary outcomes (1)
- measure
- Breast cancer specific death
- timeFrame
- January 1, 1977 to December 31, 2014
Secondary outcomes (2)
- measure
- Death from any cause
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female. 2. Operated for centimeter or subcentimeter breast cancer. Exclusion Criteria: 1. Previous breast cancer. 2. Metastatic breast cancer at diagnosis.
References
Publications (0)
Data not yet available